{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}